Figure 3.

The HBDs of IGFBP-2 suppress weight gain in IGFBP-2^−/− mice but do not affect glucose metabolism and food intake. IGBPP-2^−/− mice were treated with either a pegylated synthetic peptide containing IGFBP-2 HBD1sequence (PegHBD1, n = 8), the IGFBP-2 HBD2 sequence (PegHBD2, n = 10), or a Pegylated synthetic control peptide (Peg Ctrl, n = 18) following the procedures described in Materials and Methods for 12 weeks. WT mice (n = 8) were injected with PBS. (A) Average body weight gain of mice at weekly time points was calculated for each group. (B) Average daily of feed intake was calculated for each group. (C) Oral glucose tolerate tests were performed in all groups of mice after 12 weeks of treatment following a procedure described in Materials and Methods. Each bar value represents mean ± SE. Different letters represent significant differences between 2 treatments.